FDMT

8.39

2.63% 0.215

Handel nachbörslich: 8.39

4 D Molecular Therapeutics Inc (FDMT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$8.175

Offen:

$8.18

24-Stunden-Volumen:

638.25K

Relative Volume:

0.88

Marktkapitalisierung:

$436.02M

Einnahmen:

$20.72M

Nettoeinkommen (Verlust:

$-100.84M

KGV:

-2.5579

EPS:

-3.28

Netto-Cashflow:

$-78.56M

1W Leistung:

+2.32%

1M Leistung:

-15.85%

6M Leistung:

-68.20%

1J Leistung:

-27.67%

1-Tages-Spanne:

$8.03

$8.44

1-Wochen-Bereich:

$7.975

$8.44

52-Wochen-Spanne:

$7.90

$36.25

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Firmenname

4 D Molecular Therapeutics Inc

Sektor

Healthcare (1181)

Branche

Biotechnology (671)

Telefon

(510) 505-2680

Adresse

5858 HORTON STREET #455, EMERYVILLE

Mitarbeiter

201

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

FDMT's Discussions on Twitter

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-02-07	Fortgesetzt	Goldman	Buy
2023-10-26	Eingeleitet	RBC Capital Mkts	Outperform
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-10-18	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-07-05	Eingeleitet	Chardan Capital Markets	Buy
2023-01-30	Eingeleitet	BMO Capital Markets	Outperform
2022-11-18	Eingeleitet	H.C. Wainwright	Buy
2022-11-15	Hochstufung	Goldman	Neutral → Buy
2022-08-12	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-06-22	Eingeleitet	Jefferies	Buy
2022-01-04	Eingeleitet	SVB Leerink	Outperform
2021-01-05	Eingeleitet	BofA Securities	Buy
2021-01-05	Eingeleitet	Evercore ISI	Outperform
2021-01-05	Eingeleitet	Goldman	Neutral

Alle ansehen

4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten

02:11 AM

Vanguard Group Inc's Strategic Acquisition of Shares in 4D Molec - GuruFocus.com

02:11 AM

Oct 30, 2024

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely - Yahoo Finance

Oct 30, 2024

Oct 29, 2024

Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes - openPR

Oct 29, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 13.2% in October - MarketBeat

Oct 29, 2024

Oct 27, 2024

Assenagon Asset Management S.A. Has $16.68 Million Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

Oct 27, 2024

Oct 25, 2024

Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations - StockTitan

Oct 25, 2024

Oct 23, 2024

nVerses Capital LLC Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Oct 23, 2024

Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts

Oct 22, 2024

Oct 18, 2024

4D Molecular Therapeutics stock hits 52-week low at $8.52 By Investing.com - Investing.com Australia

Oct 18, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Oct 18, 2024

Oct 17, 2024

4D Molecular Therapeutics stock hits 52-week low at $8.52 - Investing.com India

Oct 17, 2024

Oct 16, 2024

Gene therapy for managing neovascular macular degeneration - Ophthalmology Times Europe

Oct 16, 2024

Oct 14, 2024

Recent Insider Activity Suggests Potential Gains for 4D Molecular Therapeutics Inc (FDMT) - Knox Daily

Oct 14, 2024